Estrella Immunopharma, Inc. (Nasdaq: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and ...

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over ...

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients with severe, treatment-refractory systemic lupus erythematosus.

ImmunityBio’s stock rose nearly 40% after it announced the Phase I data and Anktiva sales figures for 2025.

Optimally positioning CD19-directed therapies in the follicular lymphoma treatment sequence requires consideration of both efficacy and the risk of sacrificing future options. The introduction of CD19 ...

The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third generation anti-CD19 ...

SYDNEY & DUARTE, Calif.--(BUSINESS WIRE)--Imugene Ltd (ASX:IMU), an immuno-oncology company and City of Hope, a world-renowned independent cancer research and treatment center near Los Angeles, today ...

Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial We conducted a ...